26^th International Conference on Cancer and Oncology

According to new studies, to spread in the other parts of the body, lung cancer cells use antioxidants by activating protein BACH1 and increasing the uptake and use of sugars.  It is a well-known fact that cancer cells are exposed to oxidative stress caused by free oxygen radicals. Also, cancer cells are characterized by high uptake and use of sugar.  When cancer cells metastasize to other parts of the body, they start reducing their oxidative stress, which can happen in two ways: the cancer cells can either obtain oxidants from the diet or synthesize their own.  In about one in every three cases of lung cancer, the tumor cells have special mutations, linked to the NRF2 and KEAP1 genes, which enable them to start producing their own antioxidants. It is when the protein BACH1 is stabilized and accumulates in the cancer cells.it stimulates metastasis mechanisms, including one that orders the cancer cells to increase both the metabolism of sugar into cell fuel and lacti

In a recent study, scientists have identified several tropic plants that have anticancer properties. Know about the study in detail at : Researchers from National University of Singapore investigated the pharmacological properties of some local plants. The team mainly focused on seven plants that are used for cancer as traditional medicines. Some of these were Bandicoot Berry (Leea indica), Seven Star Needle(Pereskia bleo), Fool’s Curry Leaves and others. The team prepared extract of fresh and healthy leaves from these plants and observed their effects on cells from different types of cancer. The team found that some of these plants contain some properties against some cancer cells.  The scientists suggest that further research is required to identify the active compounds associated with these plants, that provide the anticancer effects. Cancer is the current leading cause of death in Singapore, with 1 out of 5 people develop the condition at some point in

A research team led by researchers from the University of Kansas and KU Cancer Center has developed a device which could detect cancer in a minuscule amount of blood or blood component. The device, which is called a “3D nano-patterned chip”, identifies and diagnoses cancer by filtering for exosomes, pushing them to meet the surface of the ship for analysis. Exosomes help in sending messages to the  recipient cells and communicating molecular information important in many biological functions. In the case of cancerous cells, these contain biological information that can direct tumor growth and spread in case of cancerous cells. Basically, tumors send out exosomes packaging active molecules that mirror the biological features of the parental cells. While all cells produce exosomes, tumor cells are active compared to normal cells. To test the chip’s effectiveness, the researchers used clinical samples from patients suffering from ovarian cancer, a type of cancer that is n

Tongue cancer is a type of oral cancer that usually develops in the squamous cells which form the surface of the tongue. It develops at the front surface of the tongue, though Cancer can develop in two different areas of the tongue. Cancer developed at the back of the tongue is called oropharyngeal cancer.  Squamous cell carcinoma is the most common type of tongue cancer. The primary symptoms of tongue cancer are a painful tongue and sore on the tongue that does not heal. Other symptoms of tongue cancer include: ·          stiff jaw or tongue, ·          pain in the jaw or throat, ·          a tongue ulcer, ·          a  problem in swallowing or chewing food, ·          bleeding from the tongue, ·          numbness in mouth etc                                     The symptoms of tongue cancer are similar to those of other types of oral cancers, therefore, they may not be evident in the early stages of the diseases. It is possible for p

A recent clinical trial the study has suggested that the anti-cancer drug Revlimid, also called Lenalidomide, may slow down the progression of smoldering myeloma into multiple myeloma. Revlimid is already used to treat multiple myeloma. The study revealed that individuals who received Revlimid had a reduced risk of developing multiple myeloma with initial 3 years than the individuals who were under the observation of developing the disease for the same period. Myeloma is caused by abnormal growth of plasma cells in the bone marrow. Plasma cells are a type of white blood cells in the bone marrow. Bones, immune system, kidneys, and red blood cell count are get affected by this disease. Smoldering myeloma is a pre-diseased condition in which certain proteins in the blood cause plasma cells to grow abnormally in the bone marrow. Though it does not show any symptoms of disease, however about half of the individuals diagnosed with the condition develop multiple myeloma within 5 year

The US Food and Drug Administration has approved the addition of overall survival (OS) data in labelling process of Gilteritinib, a cancer drug which was indicated for adult patients who had relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. FLT3 is a receptor tyrosine kinase with important roles in cell survival and proliferation. It is mutated in one -third of AML patients. Gliteritinib acts as an inhibitor of AXL receptor tyrosine kinase, an enzyme in humans encoded by AXL gene . The AXL gene plays a crucial role in facilitating immune escape and drug resistance by cancer cell, leading to metastatic cancers.    According to results, treatment with the FLT3-targeted therapeutic Gilteritinib has shown improved survival for patients with relapsed or refractory acute myeloid leukemia harbouring an FLT3 mutation compared with standard chemotherapy regiments. Get to know more such interesting news about oncology at: https

Cancer is a group of diseases involving abnormal growth of cells which tend to proliferate in an uncontrolled way and, in cases, to metastasize(spread). It is caused by certain changes to genes, the basic physical unit of inheritance, that control the way cells function, especially how   they grow and divide.   Normally, human cells grow and divide to form new cells as the body needs them. When cells grow old or become damaged, they die, and new cells take their place. When cancer develops, however, this orderly process breaks down. As cells become more and more abnormal, old or damaged cells survive when they should die, and new cells form when they are not needed. These extra cells can divide without stopping and may form growths called tumors.     Cancer     can involve any tissue of the body and have many different forms in each body area. Most cancers are named for the type of cell or organ in they start.

Oncology 2019 welcomes renowned oncologists, radiologists, notable scientists, researchers, academicians, research scholars, industrialists and student delegates in the “26 th International Conference on Cancer and Oncology”. The two-days event is scheduled to be held on November 11-12,2019 in London, UK. The event   has a sole aim of bringing all dignitaries under one roof to share their exceptional knowledge in cancer research and oncology , exchange their distinctive cognizance in this field   and promoting cutting edge research and health awareness in combating this deadly disease.   This event is centralised to focus on the following sessions: Opportunities in cancer biology research Cancer biomarkers Cancer epigenetics and oncogenomics Robotic oncology and several others Explore more about oncology with the experts  and share your research work in Oncology 2019